Home Featured Page 163

Featured

Latest

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Weekly Psychedelic Policy Briefing – August 16, 2026

Horizons: Perspectives on Psychedelics

Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

EDITOR PICKS

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and...

Weekly Psychedelic Policy Briefing – August 16, 2026

Horizons: Perspectives on Psychedelics

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet

Weekly Psychedelic Policy Briefing – August 16, 2026

Horizons: Perspectives on Psychedelics

Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

EDITOR PICKS

Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and...

Weekly Psychedelic Policy Briefing – August 16, 2026

Horizons: Perspectives on Psychedelics

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY